Methionine sulfoximine
Names | |
---|---|
IUPAC name
(2S)-2-Amino-4-(S-methylsulfonimidoyl)butanoic acid
| |
Other names
l-Methionine sulfoximine; MSO
| |
Identifiers | |
3D model (
JSmol ) |
|
1725509 | |
ChEBI | |
ChemSpider | |
ECHA InfoCard
|
100.016.224 |
EC Number |
|
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C5H12N2O3S | |
Molar mass | 180.22 g·mol−1 |
Related compounds | |
Related compounds
|
Buthionine sulfoximine Glufosinate |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Methionine sulfoximine (MSO, also known as MetSox
Methionine sulfoximine is composed of two different diastereomers, which are L-S-Methionine sulfoximine and L-R-Methionine sulfoximine. These affect the longevity of the model mouse for
Lou Gehrig's disease.[3] Overproduction of glutamate results to excitotoxicity, which kills the cell. Since methionine sulfoximine inhibits glutamate production in the brain, it prevents excitotoxicity. Thus, increasing the longevity of the mice.[4]
Mechanism of action
MSO is phosphorylated by glutamine synthetase. The resulting product acts as a transition state analog that is unable to diffuse from the active site, thereby inhibiting the enzyme.[5]